Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$49.02 USD
-0.72 (-1.45%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $49.40 +0.38 (0.78%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BMY 49.02 -0.72(-1.45%)
Will BMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
Alexandria Sells Asset to Redeploy in Development, Redevelopment Moves
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Other News for BMY
Edgewise Therapeutics price target raised by $10 at Leerink, here's why
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Centessa Pharmaceuticals a new buy at B Riley on sleep disorders pipeline
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life